Cargando…

Neutrophil‐to‐lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non‐small‐cell lung cancer

BACKGROUND: Although phase III trials have shown improved overall and progression‐free survival (PFS) using nivolumab compared to docetaxel in patients with non‐small‐cell lung cancer, the progressive disease ratio of nivolumab is higher than docetaxel. Furthermore, nonconventional response patterns...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeda, Takayuki, Takeuchi, Mayumi, Saitoh, Masahiko, Takeda, Sorou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166075/ https://www.ncbi.nlm.nih.gov/pubmed/30126063 http://dx.doi.org/10.1111/1759-7714.12838

Ejemplares similares

“Lazarus response” of nivolumab in a frail patient with non‐small‐cell lung cancer
por: Takeda, Takayuki, et al.
Publicado: (2017)

Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
por: Takeda, Takayuki, et al.
Publicado: (2017)

Successful management of malignant carinal involvement by “side‐by‐side” method of self‐expandable metallic stents followed by chemotherapy
por: Takeda, Takayuki, et al.
Publicado: (2017)

Successful treatment of limited-stage small-cell lung cancer in the right mainstem bronchus by a combination of chemotherapy and argon plasma coagulation
por: Takeda, Takayuki, et al.
Publicado: (2017)

Direct transbronchial administration of liposomal amphotericin B into a pulmonary aspergilloma
por: Takeda, Takayuki, et al.
Publicado: (2014)

Bilateral self-expandable metallic stents for lung cancer involving the carina
por: Takeda, Takayuki, et al.
Publicado: (2013)

Management of malignant carinal involvement using ‘side‐by‐side’ method of bilateral self‐expandable metallic stents
por: Takeda, Takayuki, et al.
Publicado: (2018)

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
por: Eso, Yuji, et al.
Publicado: (2021)

The evaluation of pretreatment neutrophil–lymphocyte ratio and derived neutrophil–lymphocyte ratio in patients with laryngeal neoplasms()
por: Eskiizmir, Gorkem, et al.
Publicado: (2018)

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
por: Nakaya, Aya, et al.
Publicado: (2018)

Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer
por: Prabawa, I Putu Yuda, et al.
Publicado: (2019)

Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
por: Gannichida, Ako, et al.
Publicado: (2022)

Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma
por: Najjar, Marc, et al.
Publicado: (2018)

Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Pediatric Parotid Cancer
por: Seng, Dongjie, et al.
Publicado: (2019)

Prognostic Utility of Pretreatment Neutrophil-Lymphocyte Ratio in Advanced Larynx Cancer
por: Kotha, Nikhil V, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictive markers in hepatoblastoma
por: Xie, Tan, et al.
Publicado: (2023)

Prognostic Relevance of Pretreatment Peripheral Neutrophil Count and Neutrophil-to-lymphocyte Ratio in Primary Cutaneous Angiosarcoma
por: AWAJI, Kentaro, et al.
Publicado: (2021)

Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients
por: Jonska-Gmyrek, Joanna, et al.
Publicado: (2018)

Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer
por: Kawahara, Takashi, et al.
Publicado: (2016)

Pretreatment Neutrophil–Lymphocyte Ratio: An Independent Predictor of Survival in Patients With Hepatocellular Carcinoma
por: Gao, Fangyuan, et al.
Publicado: (2015)

Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients
por: Cheng, Guangyan, et al.
Publicado: (2019)

Pretreatment neutrophil-to-lymphocyte ratio in peripheral blood was associated with pulmonary tuberculosis retreatment
por: Yin, Yongmei, et al.
Publicado: (2016)

The Role of Pretreatment Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in the Diagnosis of Breast Cancer: Predicting Lymph Node Metastasis
por: Eroglu, Aydan, et al.
Publicado: (2013)

Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma
por: Wang, Siqian, et al.
Publicado: (2018)

Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
por: Deng, Min, et al.
Publicado: (2017)

Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma
por: Lee, Su-Min, et al.
Publicado: (2015)

Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet−to−Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta−analysis
por: Leng, Jiali, et al.
Publicado: (2022)

Role of combining neutrophil-to-lymphocyte ratio and pretreatment body mass index in predicting progression-free survival in patients with non-small cell lung cancer treated with nivolumab
por: Dragomir, Radu, et al.
Publicado: (2021)

Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer
por: Wang, Xin, et al.
Publicado: (2016)

Predictive Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma
por: Chen, Miao-Fen, et al.
Publicado: (2018)

Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio in Mucoepidermoid Carcinoma of Pediatrics: A Multicenter Study
por: Gao, Hua, et al.
Publicado: (2020)

Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy
por: Du, Songtao, et al.
Publicado: (2021)

Neutrophils to Lymphocyte Ratio: Earliest and Efficacious Markers of Sepsis
por: Rehman, Fazal U, et al.
Publicado: (2020)

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
por: Nakamura, Yoshio, et al.
Publicado: (2016)

Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors and Reference Markers of Treatment Options for Locally Advanced Squamous Cell Carcinoma Located in the Middle and Upper Esophagus
por: Wang, Chen, et al.
Publicado: (2021)

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for the Outcome of HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma
por: Justesen, Marius Meldgaard, et al.
Publicado: (2023)

The Role of the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Markers of Disease Activity in Ankylosing Spondylitis
por: Zeb, Alam, et al.
Publicado: (2019)

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients
por: Noh, Hany, et al.
Publicado: (2013)

Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis
por: Yu, Yalian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4bq4hfactdnv9h26h4ld972bga